journal: Turkish Journal of Biochemistry

Open Access Published since January 1, 1976

Turkish Journal of Biochemistry

Türk Biyokimya Dergisi

ISSN: 1303-829X

Editor-in-chief: Doğan Yücel

Submit manuscript

About this journal

Objective

The Turkish Journal of Biochemistry (TJB), the official journal of the Turkish Biochemical Society, is an open access journal issued bi-monthly. The main objective of the journal is to promote the research and publication culture by ensuring that each published paper has added scientific value, thus ensuring international acceptance of the "readability" of the articles published in TJB. All contributions submitted for publication in TJB are single-blind peer reviewed by at least two experts in the field. TJB publishes only English-language articles. Open Researcher and Contributor ID (ORCID) is mandatory for submission.
All issues back to 2015 can be found on the TJB journal website, at the link "Issues". All back issues from 1999 to 2015, as well as the issue of the founding year, can be found HERE.

Please submit your manuscript here

Topics

Biochemistry
Clinical biochemistry
Molecular biology
Molecular genetics
Biotechnology
Bioinformatics
Bioengineering

Article formats
research articles, reviews, short communications, technical notes, case reports, opinion papers, article commentaries, letters to the editor, editorials

Your Benefits

The Turkish Journal of Biochemistry is fully open access journal. Publication costs are covered by Article Processing Charges (APC), paid by authors' affiliated institutions, funders or sponsors. Manuscripts submitted from 01 December 2020 are subject to APC. Details can be found here.

Your benefits

Wide-ranging platform for promoting local and global research in biochemistry
Basic and applied research in the field of biochemistry
High quality peer-review
Publication under the Creative Commons Attribution (CC-BY-4.0) License

Abstracting and Indexing

Turkish Journal of Biochemistry is covered by the following services:

Baidu Scholar
Cabells Journalytics
Chemical Abstracts Service (CAS) - CAplus
Chemical Abstracts Service (CAS) - SciFinder
CNKI Scholar (China National Knowledge Infrastructure)
CNPIEC - cnpLINKer
Dimensions
DOAJ (Directory of Open Access Journals)
EBSCO (relevant databases)
EBSCO Discovery Service
EMBASE
FSTA - Food Science & Technology Abstracts
Genamics JournalSeek
Google Scholar
Index Copernicus
Japan Science and Technology Agency (JST)
J-Gate
Journal Citation Reports/Science Edition
JournalGuide
JournalTOCs
KESLI-NDSL (Korean National Discovery for Science Leaders)
MyScienceWork
Naver Academic
Naviga (Softweco)
Primo Central (ExLibris)
Publons
QOAM (Quality Open Access Market)
ReadCube
Scilit
SCImago (SJR)
SCOPUS
Semantic Scholar
Sherpa/RoMEO
Summon (ProQuest)
TDNet
TEMA Technik und Management
TÜBITAK/ULAKBIM
TÜRK MEDLINE-ULUSAL ATIF INDEKSI ve TÜRKIYE ATIF DIZINI
Ulrich's Periodicals Directory/ulrichsweb
WanFang Data
Web of Science - Science Citation Index Expanded
WorldCat (OCLC)
X-MOL
Yewno Discover

Supplementary Materials

Topics

External Links

Volume 48 Issue 2

April 2023

Publicly Available May 1, 2023

Frontmatter

Page range: i-ii

Download PDF

Review

Open Access February 13, 2023

A dual role of proton pump inhibition on cancer: a critical review

Deniz Tuna Edizer, Zeynep Akcali, Asım Leblebici, Sıla Övgü Korkut, Ender Ellidokuz

Page range: 135-141

More Download PDF

Abstract

Proton pump inhibitors (PPIs) are widely used to suppress gastric acid secretion. Proton pumps belong to the family of ATPase and among them P-ATPase and V-ATPase types regulate intracellular as well as extracellular acid equilibrium. The main aim of the current survey is to present the existing literature putting forth the relation between cancer with both the use of PPIs and proton pumps from positive and negative aspects. To perform an objective study, various types of proton pumps and their relation to cancer have been taken into account. Up to date, the studies have been considered in the time range from 2011 to 2021 via various databases (PubMed, Scopus, and Google Scholar). H + /K + ATPase, located within the gastric parietal cells, is one of the most important examples of P-ATPases. The findings of the literature review along with criticism were presented as decreased P-ATPase expression can be used as a marker for gastric cancer diagnosis whereas the association of the proton pump with cancer may be mainly due to V-ATPase. In conclusion, molecular, epidemiological, and bioinformatic studies are required to enlighten the subject.

Opinion Paper

Open Access January 30, 2023

The consumption of vegetable oils and their possible participation as a neuroprotector

Diana Matías-Pérez, Marco Antonio Sánchez-Medina, Emilio Hernández-Bautista, Iván Antonio García-Montalvo

Page range: 142-144

More Download PDF

Abstract

Neurodegenerative disorders are associated with causes such as induction of oxidative stress, alterations in Ca 2+ homeostasis, abnormal protein aggregation, inflammatory processes, excitotoxicity, and apoptosis. In addition to the above, the food transition in recent years has led to changes in dietary patterns, increasing the consumption of ultra-processed and processed foods that can lead to lipotoxicity and induce oxidative stress. Nutraceutical components present in vegetable oils can be considered as an alternative for neuroprotection through the regulation of oxidative stress.

Research Articles

Open Access May 9, 2022

Analysis of inappropriate repeated laboratory testing

Cengiz Bozyigit, Merve Sena Odabasi, Melahat Dirican

Page range: 145-151

More Download PDF

Abstract

Objectives Laboratory services are an important part of the healthcare system. However many requested tests may be considered inappropriate or unnecessary. We evaluated laboratory use in a period of 3 years in terms of the inappropriate test repeats. Methods We analyzed inappropriate repeat rate (IRR) of hemoglobin A1c (HbA1c), 25-OH vitamin D [25(OH)D], thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), free thyroxine (FT4), anti-thyroid peroxidase antibody (anti-TPO), vitamin B12, folate, iron, ferritin and total cholesterol in the light of clinical guidelines. Results IRR of 3 year was found to be 10% on average (4.2–15.5%). In TSH, FT3, and FT4 parameters, IRR was between 4.2 and 5.3%, while it was between 12.9 and 15.5% for 25(OH)D, iron, ferritin, and total cholesterol. In all tests (except anti-TPO), IRRs were found to be higher in inpatients for each of the 3 years. Inappropriate repetition of total cholesterol, iron, and ferritin parameters were more frequent in men. Inappropriate repeats were performed in all parameters (except HbA1c) after a result that had been in the reference range. Conclusions Examined test repetitions were mostly inappropriate. To reduce the inappropriate laboratory test requests, it is important to analyze the causes and to ensure cooperation between laboratory specialists and clinicians.

Open Access February 16, 2023

SNP based analysis depicts phenotypic variability in heme oxygenase-1 protein

Pratichi Singh, Syed Habeeb Ahmed, Irfan Ahmad, Mohammad Mahtab Alam

Page range: 152-159

More Download PDF

Abstract

Objectives The heme oxygenase-1 (HMOX1) gene is a very critical player in cell homeostasis and takes part in heme catabolism. The HMOX1 gene possesses antioxidant, antiapoptotic anti-inflammatory, and antithrombotic properties. This study aimed to identify the deleterious SNPs which may alter the functional and structural attributes of the HMOX1 protein. Methods Deleterious SNPs were predicted using Polyphen-1, SIFT Blink, Polyphen-2, I-MUTANT 2.0, PROVEAN, PANTHER, MAPP, SNAP, and PhD-SNP. The 3D structure of the native protein was modelled using ITASSER and validated using PROCHECK. Mutant structures were created through SWISS PDB Viewer. All structures were energy-minimized using GROMACS. Protein-protein interaction (PPI) network was done using STRING. Results Three deleterious SNPs (rs146227657, rs373577583, and rs138349040 corresponding to A88D, A131V, and A206E respectively) in the HMOX1 gene were predicted. The structural analysis revealed notable differences in the structural attributes of wild-type and mutant structures. Furthermore, a PPI network was generated for the HMOX1 gene which predicts its interaction with other crucial cellular signaling molecules. Conclusions Three reported SNPs (A88D, A131V, and A206E) were identified as highly deleterious in the HMOX1 coding region that can alter the protein secondary structure, protein stability, and its conservation. This paves a new way to study the phenotype of the HMOX1 gene and its correlating diseases.

Open Access July 13, 2022

The D allele of angiotensin-converting enzyme gene insertion/deletion polymorphism is associated with the lung involvement in COVID-19

Fatma Emel Kocak, Raziye Akcilar, Fatih Kar, Ozben Ozden Isiklar, Sahinde Atlanoglu, Ozlem Genc, Fatima Yaman

Page range: 160-167

More Download PDF

Abstract

Objectives In COVID-19, severe lung involvement develops in some patients. The reason for the predisposition to lung involvement in some patients is not yet fully understood. Genetic variabilities in angiotensin-converting enzyme (ACE) may explain why some patients are more susceptible to lung injury. Thus, the ACE gene insertion/deletion (I/D) polymorphism was investigated in COVID-19 patients with and without lung involvement. Methods The study involved 216 patients who were divided into two groups as with and without pulmonary involvement according to their thoracic computed tomography (CT) scan findings. The ACE I/D gene polymorphism was determined. Results Carriers of the DD genotype had a 4.05-fold (OR=4.05, 95% CI: 1.66–9.86, p=0.001) greater incidence of pulmonary involvement. The probability of lung involvement was 2.41-fold higher in D allele carriers (OR=2.41, 95% CI: 1.62–3.60, p=0.000). The I allele was found to be protective and diminished the occurrence of lung involvement (OR=0.41, 95% CI: 0.28–0.62, p=0.000). Conclusions In COVID-19 patients, the I allele may lower the risk of lung injury and provide a protective effect. Conversely, the D allele may raise the risk of lung injury and lead to poor outcomes.

Open Access September 21, 2021

The effect of survivin gene in breast cancer risk and prognosis

Roya Mashadiyeva, Canan Cacina, Soykan Arikan, Saime Sürmen, Seyda Demirkol, Nihat Aksakal, İlhan Yaylim

Page range: 168-174

More Download PDF

Abstract

Objectives The accumulation of genetic damages in onset of cancer induce activation of protooncogenes or inactivation of tumor suppressor genes thus cause disruption of the balance between cell proliferation and programmed cell death. As a member of the apoptosis inhibitory protein family (IAP), survivin play important roles in carcinogenesis process. The evidence suggests that polymorphisms located in survivin promoter region may be important in determining genetic susceptibility of cancer. In this study, we aimed to examine a possible role of survivin −31 and −625 G/C gene polymorphisms in breast cancer. Methods A total of 160 breast cancer cases and 153 healthy controls were genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) methodology. Results Genotype and allele distributions and of −31 and −625 G/C polymorphisms were not significantly different between two groups. However, we observed the carriers of survivin −625 C/G polymorphism homozygous genotypes (GG/CC) were the significantly higher in patients with tumor necrosis (p=0.047). Conclusions Our results suggest that survivin −625 C/G polymorphism may be related with tumor prognosis, but we are opinion of that our result require to be validated in larger samples and further comprehensive research may explore the correlation.

Open Access February 23, 2023

Increase of Claudin-5, ICAM-1 and eNOS expressions in human brain endothelial cells by ammonium chloride

Nurul Farhana Jufri, Tharshini Salyam, Farah Wahida Ibrahim, Dharrshine Yoganathan, Asmah Hamid, Mazlyzam Abdul Latif, Siti Nurdiyana Mohd Saleh, Nor Atikah Safirah Juhari

Page range: 175-182

More Download PDF

Abstract

Objectives Lysosomal dysfunction could lead to a failure in the degradation process of waste materials, especially for the elimination of aggregated, misfolded and senescence proteins or organelles. Human brain endothelial cells (HBECs) are a part of the blood-brain barrier and any disruption of lysosomal functions could affect the cellular functions of the HBECs. Protein expression studies on the cells could give an insight to associate lysosomal dysfunction on HBECs homeostasis. The aim of this study was to measure the cellular changes via the expression of several proteins such as Claudin-5, which is a tight junction protein; intracellular adhesion molecule 1 (ICAM-1), an inflammatory marker and endothelial nitric oxide synthase (eNOS), which provides nitric oxide (NO) for vasodilation. These components are important in maintaining homeostasis as the imbalance could lead to endothelial impairment linked brain related disorders such as neurodegenerative disease. Methods HBECs were treated with 10 mM ammonium chloride, which is a lysosome inhibitor for 1 h. The protein lysates were collected and subjected for ICAM-1 and Claudin-5 measurement by capillary immunoassay instrument, while eNOS by ELISA. Results Claudin-5 and ICAM-1 expression significantly increased (p<0.05). The ELISA results showed eNOS increment (p<0.001) compared to control. Lysosome inhibitor could be associated with accumulation of organelles that can stimulates inflammation and initial cellular responses. Conclusions Inhibition of lysosome by the inhibitor increases protein expressions related with endothelial function.

Open Access February 23, 2023

The effect of different anti-inflammatory treatment strategies on process of atherosclerosis in ankylosing spondylitis patients

Mehmet Akif Bozdayi, Hasan Ulusal, Neytullah Turan, Ozlem Altindag, Mustafa Orkmez, Seyithan Taysi, Mehmet Tarakcioglu

Page range: 183-189

More Download PDF

Abstract

Objectives Our aim in this study was to examine the effects of different anti-inflammatory treatment strategies on the process of atherosclerosis, which is an important cause of mortality in ankylosing spondylitis (AS) patients, by examining the possible effect of treatments on inflammation, lipid profile and oxidative stress parameters in patients with AS. Methods In this study, 32 healthy volunteers served as the control group in addition to a total of 76 AS patients who were divided into two groups according to whether they were receiving anti-TNF medications or not. We assessed the levels of inflammation, oxidative stress, lipid profile parameters, and oxidized low-density lipoprotein (oxLDL). The atherogenic index of plasma (AIP), non-HDL cholesterol levels, BASDAI, and BASFI scores were also calculated. Results AS patient groups and the control group had similar lipid profile parameters, thiol-disulfide homeostasis metrics, non-HDL cholesterol, oxLDL, and AIP levels (p>0.05). In contrast to AS patients receiving non-anti-TNF treatment, the BASDAI and BASFI scores, ESR, and CRP levels were lower in AS patients receiving anti-TNF treatment (p<0.05). In contrast to the controls, AS patients demonstrated high TOS and OSI values (p<0.05). Conclusions AS patients face increased oxidative stress that does not correlate with inflammatory status and disease activation level. Anti-TNF alpha treatment may reduce some risk factors of atherosclerotic CVD in AS patients.

Open Access March 1, 2023

Genetic dissection of the Mastl-Arpp19/Ensa-PP2A-B55δ pathway in mammalian cells

Muhammed Kasim Diril, Mehmet Erguven

Page range: 190-202

More Download PDF

Abstract

Objectives Mastl is an essential kinase required for inhibition of the phosphatase activity directed toward Cdk1/cyclin B substrates during mitosis. Mastl phosphorylates two small evolutionarily conserved proteins, Arpp19 and Ensa converting them into strong inhibitors of PP2A-B55δ. Mastl-Arpp19/Ensa-PP2A regulatory pathway has been mainly studied in Xenopus egg extracts and Drosophila using biochemical and genetic approaches. Studies in mammalian cells and genetically modified mouse models have suggested distinct but important functions for Arpp19 and Ensa, in mitosis and S-phase, respectively. A detailed comparative analysis of the Arpp19 and Ensa functions in mammalian cells has not been performed. Methods We utilized Mastl conditional knockout (CKO) mouse embryonic fibroblasts (MEF), to investigate the roles of Mastl-Arpp19/Ensa-PP2A pathway components in mitosis and cellular proliferation. We used viral transduction for overexpression or silencing of these genes in conjunction with inducible genetic Mastl knockout to assess their roles in relation to each other. Results We show that, Arpp19 is expressed at significantly higher levels in MEFs in comparison to Ensa. Silencing of Arpp19, but not Ensa, results in reduced cellular proliferation. Overexpression of WT Arpp19 or its phosphomimetic mutant (S67D) partially restores mitosis arrest duration in Mastl knockout MEFs, however cellular proliferation block cannot be rescued. Silencing of B55δ expression has a similar outcome as Arpp19 overexpression, underscoring the opposite roles of these genes in mitosis. Conclusions Our results show that Arpp19 is the major Mastl substrate during mitotic division of MEFs. Ensa expression is low and it is not essential for cell cycle.

Open Access March 31, 2023

Investigation into miRNA profile in patient groups with and without ST elevation

Onur Bobusoglu, Senay Balci, Ahmet Gundes, Ahmet Camsari, Lulufer Tamer

Page range: 203-208

More Download PDF

Abstract

Objectives Because acute myocardial infarction (AMI) may occur suddenly and cannot be predicted, it is critical to identify early diagnosis markers. In recent years, in addition to the developing diagnostic methods, other markers that may be related to the diagnosis of AMI are miRNA molecules. The specificity of miRNAs involved in the pathogenesis of atherosclerosis and regulation of cardiac functions has been shown. The present study aimed to investigate the changes in miRNA expression levels in MI patients with ST-elevation (STEMI) and without ST elevation (NSTEMI). Methods In this study, 25 patients with STEMI, 25 with NSTEMI, and 20 healthy participants were included. Expression analysis of miRNAs isolated from the plasma of individuals was performed using high-throughput real-time PCR. Results Compared with the control group, miR-221-3p and miR-30d-5p were downregulated, while miR-25-3p, miR-92a-3p, miR-34a-5p and miR-150 upregulated in the patient group with NSTEMI; miR-221-3p, miR-25-3p, miR-30d-5p and miR-92a-3p were downregulated while miR-208a-3p was upregulated in patients with STEMI (p>0.05). Conclusions In conclusion, miRNAs may be an early biomarker for diagnosing AMI; however, further and larger studies are needed.

Open Access April 5, 2023

Prognostic value of total thiol and D-dimer in patients hospitalized with COVID-19

Didem Barlak Keti, Sabahattin Muhtaroglu, Orhan Yildiz, Hatice Saraçoglu

Page range: 209-214

More Download PDF

Abstract

Objectives The lack of specific treatment for COVID-19 and the fact that the clinical course differs between individuals makes it difficult to predict the prognosis. The aim was to investigate the prognostic value of total thiol, D-dimer, procalcitonin (PCT), ischemia-modified albumin (IMA), and complete blood count (CBC) in patients hospitalized with COVID-19. Methods 100 consecutive patients were hospitalized with COVID-19, confirmed by RT-PCR between December 2021-March 2022 and 30 healthy control participated in the study. According to the World Health Organization guideline, two groups were created as critical and non-critical. D-dimer, PCT, IMA, total thiol levels, and CBC were analyzed. Receiver-operating characteristic curves (ROC) were utilized to determine an optimum cut-off value for distinction. Results We defined a cut-off value of 1,030 μg/L for D-dimer (Area Under Curve, AUC): 0.691; p=0.001) and 148 μmol/L for total thiol (AUC: 0.749; p<0.001) via ROC analysis. The combination of D-dimer and total thiol reached 65% positive predictive value (PPV) and 80% negative predictive value (NPV). Conclusions D-dimer and total thiol may help predict critical patients with COVID-19.

Case Report

Open Access March 2, 2023

The effect of heterophilic antibody interference in thyroglobulin measurement on different immunoassay devices

Ismet Gamze Kutluay, Mehmet Akif Bozdayi, Hasan Ulusal, Mehmet Tarakcioglu

Page range: 215-217

More Download PDF

Abstract

Objectives Serum thyroglobulin (Tg) is a biochemical marker used in the follow-up of patients with differentiated thyroid cancer (DTC), but heterophile antibody interference may limit the clinical use of Tg. Case presentation In the first-year follow-up of a 31-year-old female patient who received treatment for papillary thyroid CA, a clinically significant difference was found in the Tg values measured by two different brand devices with similar measurement methods. Conclusions Despite the use of state-of-the-art laboratory equipment, heterophile antibodies in immunoassay analysis can still cause false high Tg measurements. Our case report shows that analytical errors can be avoided with attention and effective communication between clinicians and laboratory specialists. In this way, patients will be prevented from being misdiagnosed and/or exposed to treatment.

Ahead of Print / Just Accepted

Ahead of Print / Just Accepted

Volume 48 (2023)

Volume 47 (2022)

Volume 46 (2021)

Volume 45 (2020)

Volume 44 (2019)

Volume 43 (2018)

Volume 42 (2017)

Volume 41 (2016)

Volume 40 (2015)

5-year Journal Impact Factor	0.499
CiteScore	0.8
Journal Impact Factor	0.481
Journal Citation Indicator	0.07
SCImago Journal Rank	0.152
Source Normalized Impact per Paper	0.206

Submit

Submission
Manuscripts should be submitted on-line via submission system at https://mc.manuscriptcentral.com/tjbiochem

Your benefits of publishing with us

Easy-to-use online submission, peer review, and publication system
Short turnaround times
High quality independent peer-review
Each article easily discoverable because of Search Engine Optimization (SEO) and comprehensive abstracting and indexing services
Secure archiving by De Gruyter and the independent archiving service Portico
Professional sales and marketing activities
Authors retain copyright – all articles are published under the Creative Commons Attribution 4.0 International (CC BY 4.0) License

Submission process

Prepare your manuscript according to the guidelines available here
Submission of your paper via the submission management tool
Double-blind peer review process (step by step guidance)
Quick decision on your paper
Accepted articles are published online first

Please note

Make sure the title is provided in correct English, Turkish is optional
Title page should be submitted as separate file (main title, short title, author names and affiliations, full address of corresponding author, keywords)
Figures (tiff or jpeg) should be uploaded as separate files. Figures should have a minimum resolution of 600 dpi
Authors have to fill in and upload the Template for Ethical and Legal Declarations. Instructions on how to make declarations can be found here.
In case of reproducing tables, figures, graphics etc., permission must be obtained and sent to the TJB editorial office along with the submission
All articles published in TJB are fully open access - please fill in the License to Publish and upload it together with your mansucript
If you have any general questions please visit our FAQ page for authors
Editorial correspondence other than manuscript submission can be sent to editor@turkjbiochem.com

We look forward to receiving your manuscript!

Editorial

EDITOR IN CHIEF [BAŞ EDİTÖR]
Doğan Yücel, Department of Medical Biochemistry, Faculty of Medicine, Lokman Hekim University, Ankara, TURKEY

ASSOCIATE EDITORS [BÖLÜM EDİTÖRLERİ]
Sedat Abuşoğlu, Department of Medical Biochemistry, Faculty of Medicine, Selçuk University, Konya, TURKEY
Reᶊat Apak, Department of Chemistry, Faculty of Engineering, İstanbul University Cerrahpaºa Research Information System, İstanbul, TURKEY
Ebubekir Bakan, Department of Biochemistry, Faculty of Medicine, Atatürk University, Erzurum, TURKEY
Sreeparna Banerjee, Department of Biological Sciences, Middle East Technical University, Ankara, TURKEY
Emine Bayraktar, Department of Chemical Engineering, Faculty of Engineering, Ankara University, Ankara, TURKEY
Ebru Bodur, Department of Medical Biochemistry, Faculty of Medicine, Hacettepe University, Ankara, TURKEY
Murat Bolayırlı, Department of Biochemistry, Faculty of Medicine, Cerrahpaşa İstanbul University, İstanbul, TURKEY
Abdurrahman Coşkun, Department of Medical Biochemistry, School of Medicine, Acıbadem University, İstanbul,TURKEY
Özlem Dalmızrak, Department of Medical Biochemistry, Faculty of Medicine, Near East University, Nicosia, TRNC
Birsen Can Demirdöğen, Department of Biomedical Engineering, TOBB University of Economics and Technology, Ankara, TURKEY
Aylin Sepici Dinçel, Department of Medical Biochemistry, Faculty of Medicine, Gazi University, Ankara, TURKEY
Suat Erdoğan, Department of Medical Biology, School of Medicine, Trakya University, Edirne, TURKEY
Ammad Ahmad Farooqi, Islamabad, Pakistan
Uzay Görmüş, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Solna, SWEDEN
Merve Sibel Güngören, Duzen Lab., Ankara, TURKEY
Erdal Karaöz, Department of Histology and Embryology, Faculty of Medicine, İstinye University, İstanbul, TURKEY
Levent Kayrın, Department of Medical Biochemistry, Faculty of Medicine, Kyrenia University, Kyrenia , TRNC
Semra Koçtürk, Department of Medical Biochemistry, School of Medicine, Dokuz Eylül University, İzmir, TURKEY
Işıl Aksun Kurnaz, Department of Molecular Biology and Genetics, Gebze Technical University, Kocaeli, TURKEY
Melek Özkan, Department of Environmental Engineering, Gebze Technical University, Kocaeli, TURKEY
Yeşim Özkan, Department of Biochemistry, Faculty of Pharmacy, Gazi University, Ankara, TURKEY
Oytun Portakal, Department of Medical Biochemistry, Faculty of Medicine, Hacettepe University, Ankara, TURKEY
Ebru Saatçi, Department of Biology, Faculty of Arts & Sciences, Erciyes University, Kayseri, TURKEY
Muhittin Serdar, Department of Medical Biochemistry, School of Medicine, Acıbadem University, İstanbul, TURKEY
Çağdaş Son, Department of Computer Engineering, Middle East Technical University, Ankara, TURKEY
Alaattin Şen, Department of Biology, Faculty of Arts & Sciences, Pamukkale University, Denizli, TURKEY
Mehmet Şeneş, Department of Biochemistry, Ankara Education and Research Hospital, Ankara, TURKEY
Ajlan Tükün, Department of Medical Genetics, Faculty of Medicine, Ankara University,Ankara,TURKEY
Hamdi Uysal, Department of Biochemistry, Faculty of Veterinary Medicine, Ankara University, Ankara, TURKEY
İlhan Yaylım, Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, İstanbul University, İstanbul, TURKEY
Fatma Meriç Yılmaz, Department of Medical Biochemistry, Faculty of Medicine, Ankara Yıldırım Beyazıt University, Ankara, TURKEY
Meral Yüksel, Department of Medical Laboratory Techniques, Vocational School of Health Services, Marmara University, Istanbul, TURKEY

STATISTICS EDITORS [İSTATİSTİK EDİTÖRLERİ]
Erdal Coşgun, Microsoft Genomics Research Group, Redmond, WA, USA
Sevilay Karahan, Department of Biostatistics, Faculty of Medicine, Hacettepe University, Ankara, TURKEY
Jale Karakaya, Department of Biostatistics, Faculty of Medicine, Hacettepe University, Ankara, TURKEY

TECHNICAL EDITORS (TEKNİK EDİTÖRLER)
Tülin Bayrak, Department of Medical Biochemistry, Faculty of Medicine, Ordu University, Ordu, TURKEY
Birsen Can Demirdöğen, Department of Biomedical Engineering, TOBB University of Economics and Technology, Ankara, TURKEY
Emel Çolak, Department of Medical Biochemistry, Ankara Education and Research Hospital, Ankara , TURKEY
Merve Sibel Güngören, Duzen Lab., Ankara, TURKEY
Duygu Eryavuz Onmaz, Department of Medical Biochemistry, Faculty of Medicine, Selçuk University, Konya, TURKEY
Elvan Laleli Şahin, Dallas, USA
Duygu Şahin, Department of Medical Biochemistry, Istanbul Aydın University, Istanbul, TURKEY
Z. Onur Uygun, Department of Medical Biochemistry, Faculty of Medicine, Ege University, İzmir, TURKEY
Oğuzhan Zengi, Department of Medical Biochemistry, Bağcılar Training and Research Hospital, İstanbul, TURKEY

CORRESPONDENCE [YAZI İŞLERİ]
Nermin Şahan, Hirfanlı Sokak 9/3 Gaziosmanpaşa 06700 Ankara, TÜRKİYE

EDITORIAL BOARD [EDİTÖRLER KURULU]
Khosrow Adeli, Molecular Medicine, Research Institute, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, CANADA
Cezmi Akdiᶊ, University Zurich, Swiss Institute of Allergy and Asthma Research (SIAF), Davos, SWITZERLAND
Mübeccel Akdiᶊ, University Zurich, Swiss Institute of Allergy and Asthma Research (SIAF), Davos, SWITZERLAND
Diler Aslan, Department of Biochemistry, Faculty of Medicine, Pamukkale University, Denizli, TURKEY
Cumhur Bilgi, Özel Koru Hastaneleri, Department of Biochemistry, Ankara, TURKEY
Anyla Bulo-Kasneci, Laboratory Department, University Hospital Center "Mother Teresa", Tirana, ALBANIA
Orhn Değer, Department of Medical Biochemistry, Faculty of Medicine, Karadeniz Technical University, Trabzon, TURKEY
Elif Demirkan, Department of Biology, Faculty of Arts & Sciences, Uludağ University, Bursa, TURKEY
Z. Günnur Dikmen, Department of Biochemistry, Faculty of Medicine, Hacettepe University, Ankara, TURKEY
Miral Dizdaroğlu, Biomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, MD, USA
Mustafa B. A. Djamgoz, Department of Life Sciences, Faculty of Natural Sciences, Imperial College, London, UNITED KINGDOM
Figen Erkoç, Emeritus, Ankara, TURKEY
Gökhan Hotamişlıgil, Department of Genetics and Complex Diseases, Harvard School of Public Healt, Boston, USA
Ivan G. Ivanov, Institute of　Molecular Biology, Bulgarian Academy of Sciences, Sofia, BULGARIA
Erdal Karaöz, Department of Histology and Embryology, Faculty of Medicine, Istinye University, İstanbul, TURKEY
Mehmet Kesimer, Department of Pathology and Laboratory Medicine, Marsico Lung Institute, University of North Carolina at Chapel Hill, NC, USA
İrfan Küfrevioğlu, Department of Chemistry, Faculty of Art & Sciences, Atatürk University, Erzurum, TURKEY
Nada Majkic-Singh, Institute of Medical Biochemistry, Pharmaceutical Faculty and Clinical Centre of Serbia, Belgrade, SERBIA
Gülgün Oktay, Department of Medical Biochemistry, Faculty of Medicine, University of Dokuz Eylül, İzmir, TURKEY
İ. Hamdi Öğüş, Emeritus, TRNC
Yeşim Özarda, Department of Medical Biochemistry, Faculty of Medicine, Uludağ University, Bursa, TURKEY
Tomris Özben, Department of Medical Biochemistry, Faculty of Medicine, Akdeniz University, Antalya, TURKEY
Nazmi Özer, Faculty of Pharmacy, Girne American University, Nicosia TRNC
Israel Pecht, Department of Immunology, Weizmann Institute of Science, Rehovot, ISRAEL
Mario Plebani, Department of Medical Sciences, University of Padova, Padova, ITALY
Demetrios Rizos, Hormonal and Biochemical Laboratory, Aretaieio Hospital, University of Athens, Athens, GREECE
George Russev, Bulgarian Academy of Sciences, Institute of Molecular Biology, Sofia, BULGARIA
Fahri Saatçioğlu, Department of Biosciences, University of Oslo, Oslo, NORWA
Ferhan Girgin Sağın, Department of Medical Biochemistry, Faculty of Medicine, University of Ege, İzmir, TURKEY
Aziz Sancar, Deparment of Biochemistry and Biophysics, University of North Carolina School of Medicine, Chapel Hill, NC, USA
Praveen Sharma, All India Institute of Medical Sciences, Jodhpur, INDIA
Emin Sofic, Department of Chemistry, Faculty of Science,University of Sarajevo, Sarajevo, BOSNIA AND HERZEGOVIA
Eser Sözmen, Department of Medical Biochemistry, Faculty of Medicine, University of Ege, İzmir, TURKEY
Abdullah Tuli, Department of Medical Biochemistry, Faculty of Medicine, Çukurova University, Adana, TURKEY
Ali Ünlü, Department of Biochemistry, Faculty of Medicine, Selçuk University, Konya, TURKEY
Sedef Yenice, Department of Clinical Chemistry, Group Florence Nightingale Hospitals, İstanbul, TURKEY

EDITORIAL OFFICE
Heike Jahnke
Walter de Gruyter GmbH
Genthiner Str. 13
10785 Berlin
Germany
Tel. +49-30-26005-220
E-mail: Heike.Jahnke@degruyter.com

(Deutsch)

Type: Journal
Language: English
Publisher: De Gruyter
First published: January 1, 1976
Publication Frequency: 6 Issues per Year
Audience: researchers in chemistry, physics, engineering, pharmacology, molecular biology, biomedicine, and clinicians, addressing recipients in academic, industrial, and regulatory environments, the informed public and policymakers.